Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04913129
Other study ID # 21-002693
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 4, 2021
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is being done to find out what the longer-term physiological consequences of COVID-19 are, and to determine if exercise therapy can help improve lung function, heart function and overall fitness, and reduce symptoms in people recovering from SARS-CoV-2.


Description:

The purpose of this research is to see if taking part in structured exercise training will improve the ability to exercise, the function of the lungs and the function of the heart, and reduce symptoms of fatigue and breathlessness in people recovering from COVID-19. After enrollment all patients will complete exercise testing, lung function testing, and cardiac imaging. Patients will be randomized to either 8 weeks of exercise training (4-5 times per week) or will continue standard medical care. All patients will undergo detailed exercise testing, lung function testing, and cardiac imaging after the intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 75 Years
Eligibility Inclusion Criteria: - Aged 21 to 75 years. - History of RT-PCR proven SARS-CoV-2 infection. - Deemed 'recovered' from SARS-CoV-2 infection. - Not clinically obese (BMI = 36) and/or suffer from musculoskeletal or other conditions that would limit exercise participation. - No evidence of cardiac ischemia at rest or during exertion (via ECG). - Able to provide written informed consent. Exclusion Criteria: - Individuals less than 21 or more than 75 years old. - Not able to take part in structured exercise training due to injury or other conditions that would put person at risk during exercise. - Unable to provide written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise Training
8 week home-based exercise therapy 4-5 times/week

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximal oxygen update (VO2max) measured in mL/kg/min VO2max is the maximal oxygen consumed during an exhaustive exercise test 8 weeks
Secondary Peak exercise work rate (Wpeak) measured in Watts Wpeak is the highest achieved power during a maximal incremental cycle exercise test 8 weeks
Secondary Forced vital capacity (FVC) measured in L FVC is the largest amount of air that can be exhaled from the lungs in one maximal breath 8 weeks
Secondary Forced expiratory volume in 1 second (FEV1) measured in L FEV1 is the largest amount of air that can be exhaled from the lungs in the first second of one maximal breath 8 weeks
Secondary Maximal inspiratory pressure (MIP) measured in cmH2O Highest inspiratory muscle pressure (i.e. inspiratory muscle strength) during a maximal inspiratory effort 8 weeks
Secondary Maximal expiratory pressure (MEP) measured in cmH2O Highest expiratory muscle pressure (i.e. expiratory muscle strength) during a maximal expiratory effort 8 weeks
Secondary Left ventricular contractile function measured as % fractional area change (LV FAC) LV FAC is a measure of overall contractile function of the LV 8 weeks
Secondary Right ventricular contractile function measured as % fractional area change (RV FAC) RV FAC is a measure of overall contractile function of the RV 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3